Biovest May Be The Next Dendreon (BVTI, ABPIQ, DNDN)
One of the largest percentage gainers out there with data released at the American Society of Clinical Oncology was none other than an OTC micro-cap company called Biovest International, Inc. (OTC: BVTI). Technically, this is a majority owned subsidiary company of Accentia Biopharmaceuticals, Inc. (OTC: ABPIQ). The company has nothing to do with Dendreon Corp. (NASDAQ: DNDN) in the business, but the targets of the potential products use the body’s own immune system to fight tumors strike a similar interest. And this weekend’s data released was far better than most were expecting from a company of this size.
We also covered this one in our weekly “10 Stocks under $10″ Newsletter as one with a big win under its belt. The percentages of success were that large. As noted:
Read more
Latest from 247Wallst.com- Latest from VSInvestor
- Top Day Trader Alerts (AIG, BPAX, C, DVN, ICO, TEAR)
- Top Day Trader Alerts (AEO, AIG, C, FACT, FNM, FRE, SOLR, ITMN)
- Russell 2000 Top Performers Since the Crash (ATSG, AXL, ARM, BZ, CKEC, CTIC, CNO, GPRE, HGSI, LZB, PIR, PWER, PMI, UIS, VNDA)
- Top Day Trader Alerts (CSCO, CNAM, NBG, FSLR, JSDA, DRYS, FEED, BWEN, FMD)
- DryShips… Rumors of a Rumor (DRYS)
